Following the introduction of prostate specific antigen (PSA) screening, the rates of men presenting with metastatic disease is falling and the opportunity to intervene and alter the natural history of prostate cancer in select, high-risk patients has never been greater. This evidence concerns the gene KLK3 and prostate cancer.